Ursula Matulonis
乌苏拉·马图洛尼斯
MD
Chief, Division of Gynecologic Oncology妇科肿瘤学部主任
👥Biography 个人简介
Chief of Gynecologic Oncology at Dana-Farber and internationally recognized expert in ovarian cancer therapeutics. Specializes in PARP inhibitors, antibody-drug conjugates (ADCs), and novel targeted agents, with leadership in defining platinum-resistant ovarian cancer treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PARP Inhibitor Research
Conducted pivotal trials of olaparib and rucaparib in BRCA-mutated and homologous recombination-deficient ovarian cancer, establishing biomarker-driven treatment selection.
Antibody-Drug Conjugates
Led early clinical evaluation of mirvetuximab soravtansine (anti-FRα ADC), contributing to its FDA approval for platinum-resistant ovarian cancer.
Platinum-Resistant Ovarian Cancer
Developed treatment algorithms and conducted multiple phase II trials defining optimal sequencing in platinum-resistant recurrent ovarian cancer.
Representative Works 代表性著作
Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer (SORAYA)
Journal of Clinical Oncology (2023)
Key trial contributing to FDA approval of first FRα-targeted ADC for platinum-resistant ovarian cancer, a major therapeutic advance.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2)
The Lancet Oncology (2017)
Defined genomic loss of heterozygosity as a predictive biomarker expanding PARP inhibitor benefit beyond BRCA mutations.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Bradley J. Monk
University of Arizona / HonorHealth
Kathleen N. Moore
Stephenson Cancer Center, University of Oklahoma
Ana Oaknin
Vall d'Hebron University Hospital
Shannon Neville Westin
The University of Texas MD Anderson Cancer Center
关注 乌苏拉·马图洛尼斯 的研究动态
Follow Ursula Matulonis's research updates
留下邮箱，当我们发布与 Ursula Matulonis（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment